1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Sunday January 28, 2018
17:00Opening Remarks
17:15Title to be announced
Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)
18:15Poster Session
20:15End of Day 1
Monday January 29, 2018
Session 1: Advances in Synthetic Methods
Session Chair
Nuno MAULIDE
(UNIVERSITY OF VIENNA, Vienna, Austria)
08:30Assembly Line Synthesis
Varinder K. AGGARWAL
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)
09:00Photochemical Reactions en route to Structurally Complex Molecules
Thorsten BACH
(TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany)
09:30Coffee Break
10:00Small Ring Chemistry
Ilan MAREK
(ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel)
10:30Open Slot for an Oral Communication selected from submitted Abstracts
Session 2: Addressing Preclinical Toxicity – Approaches and Lessons Learned
Session Chair
Andy PEAT
(GLAXOSMITHKLINE, United States)
17:30Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies
Peter DRAGOVICH
(GENENTECH INC., San Francisco, United States)
18:00Utilizing in Depth Understanding of a Molecules Off Target Profile to Tailor Clinical and Preclinical Safety Assessments
Douglas THOMSON
(CELLZOME GMBH, Heidelberg, Germany)
18:30Coffee Break
19:00Overcoming Drug Bioactivation in Lead Optimization: Case Studies
Axel PÄHLER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
19:30Open Slot for an Oral Communication selected from submitted Abstracts
20:00Panel Discussion
20:45End of Day 2
Tuesday January 30, 2018
Session 3: Advances in Lead Generation
Session Chair
Doris RIETHER
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)
08:30ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation
Eva María MARTÍN
(ELI LILLY, Madrid, Spain)
09:00A Chemist’s Guide to Modern Phenotypic Drug Discovery
Monika ERMANN
(EVOTEC LTD, Oxfordshire, United Kingdom)
09:30Coffee Break
10:00Open Slot for an Oral Communication selected from submitted Abstracts
10:30From Multiple Hit Series to (Pre)Clinical Candidates Using DNA Encoded Library Technology
Sanne SCHRØDER GLAD
(NUEVOLUTION A/S, Copenhagen, Denmark)
Session 4: Chemical Biology in Drug and Target Discovery
Session Chair
Matthew HAYWARD
(PFIZER, Groton, United States)
17:30Biosensors for Measuring Metabolite and Drug Concentrations in Living Cells
Kai JOHNSSON
(SWISS FEDERAL INSTITUTE OF TECHNOLOGY IN LAUSANNE (EPFL), Lausanne, Switzerland)
18:00Open Slot for an Oral Communication selected from submitted Abstracts
18:30Coffee Break
19:00Activity-based proteomics – Protein and Ligand Discovery on a Global Scale
Benjamin CRAVATT
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)
20:00End of Day 3
Wednesday January 31, 2018
Session 5: Alternative Modalities
Session Chair
Philippe NANTERMET
(MERCK, SHARP & DOHME, West Point, United States)
08:30Discovery Chemistry Modalities: Chemistry on the Macromolecular Scale
David TELLERS
(MERCK & CO. INC (MSD), West Point, United States)
09:00New Modalities for Challenging Targets in Drug Discovery
Eric VALEUR
(ASTRAZENECA R&D GOTHENBURG, Mölndal, Sweden)
09:30Coffee Break
10:00Messenger RNA as A Novel Therapeutic Approach
Matthew STANTON
(MODERNA THERAPEUTICS, Cambridge, United States)
10:30Open Slot for an Oral Communication selected from submitted Abstracts
Session 6: Late Stage Functionalization
Session Chair
Guido KOCH
(NOVARTIS PHARMA AG, Basel, Switzerland)
17:30Title to be announced
Matthew GAUNT
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
18:00Title to be announced
Nicolai CRAMER
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, Lausanne, Switzerland)
18:30Coffee Break
19:00Catalytic Approaches to Simplifying Synthesis
Darren J. DIXON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
19:30Open Slot for an Oral Communication selected from submitted Abstracts
20:00End of the Scientific Programme on Day 4
21:00Conference Dinner
23:00End of Day 4
Thursday February 1, 2018
Session 7: Challenges and Opportunities in Fragment Based Drug Discovery
Session Chair
Alison WOOLFORD
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)
08:30Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening
Tom HEIGHTMAN
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)
09:00The Impact of Fragments on Drug Discovery
Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)
09:30Coffee Break
10:00Title to be announced
Mairi SIME
(BEATSON INSTITUTE FOR CANCER RESEARCH, Bearsden Glasgow , United Kingdom)
10:30Open Slot for an Oral Communication selected from submitted Abstracts
Session 8: Drug Discovery Tales
Session Chair
Sarah SKERRATT
(VERTEX PHARMACEUTICALS, Oxon, United Kingdom)
17:30Open Slot for an Oral Communication selected from submitted Abstracts
17:50Open Slot for an Oral Communication selected from submitted Abstracts
18:10Open Slot for an Oral Communication selected from submitted Abstracts
18:30Coffee Break
19:45Closing Remarks
20:00End of Symposium

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys